Nasdaq
$311.50▲ 0.02%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $9.18BShares out 29.5M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
14- 10.15Pre-market26.10.15 20:028-KKey event#●●●#●●●#●●●
Krystal Biotech, Inc.Bullish
Krystal Biotech announced positive clinical data from its pilot study of KB113 for treating basal cell carcinoma in patients with Gorlin syndrome. In a study of three patients, over 80% of assessed lesions showed regression, with evidence of an abscopal effect in non-injected lesions and a favorable safety profile. The company is currently in discussions with the FDA regarding further clinical development plans.…more
$311.50+0.02%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.17Overnight26.09.17 09:054Ownership
Krystal Biotech, Inc.
Insider Dino A. Rossi of Krystal Biotech, Inc. filed a Form 4 report on September 16, 2026, regarding changes in beneficial ownership of securities as of September 14, 2026. This is a standard regulatory filing detailing insider transaction activity.…more
$311.50+0.02%vs prev closeView filingShare - 9.17Overnight26.09.17 09:034Ownership
Krystal Biotech, Inc.
Krystal Biotech insider Sutherland Everett Rand filed a Form 4 report on September 16, 2026, regarding changes in beneficial ownership of securities as of September 14, 2026. This filing serves as an official disclosure of insider equity transactions.…more
$311.50+0.02%vs prev closeView filingShare
13 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 2d agoPre-market26.10.22 21:00#●●●#●●●
Krystal Biotech to Report Q3 2026 Financial Results on Nov 2
Krystal Biotech announced it will release its third quarter 2026 financial results before the U.S. market opens on November 2, 2026. Management will host a conference call and webcast to discuss the results and provide a business update.…more
$311.50+0.02%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 10.15Pre-market26.10.15 20:05
●●●●●●●● ●●●●● ●●●●●●
Krystal Biotech announced that its KB113 immunotherapy showed over 80% regression of basal cell carcinoma lesions in Gorlin syndrome patients. The data demonstrated a potential abscopal effect, supporting the initial proof of concept for the treatment.…more
$311.50+0.02%vs prev closeShareBenzinga - 9.3Pre-market26.09.03 21:00
●●●●●●●● ●●●●● ●●●●●●
Krystal Biotech announced its participation in the 2026 Cantor Global Healthcare Conference on September 10. Management will engage in a fireside chat and host investor meetings to discuss the company's progress.…more
$311.50+0.02%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report